Literature DB >> 35925400

Outcomes of biologic versus synthetic mesh in CDC class 3 and 4 open abdominal wall reconstruction.

Michael Katzen1, Sullivan A Ayuso1, Jana Sacco1, Dau Ku1, Gregory T Scarola1, Kent W Kercher1, Paul D Colavita1, Vedra A Augenstein1, B Todd Heniford2.   

Abstract

INTRODUCTION: Abdominal wall reconstruction (AWR) in a contaminated field is associated with an increased risk of wound complications, infection, and reoperation. The best method of repair and mesh choice in these operations have generated marked controversy. Our aim was to compare outcomes of patients who underwent AWR with biologic versus synthetic mesh in CDC class 3 and 4 wounds.
METHODS: A prospective, single-institution database was queried for AWR using biologic or synthetic mesh in CDC Class 3 and 4 wounds. Hernia recurrence and complications were measured. Multivariable logistic regression was performed to identify factors predicting both.
RESULTS: In total, 386 patients with contaminated wounds underwent AWR, 335 with biologic and 51 with synthetic mesh. Groups were similar in age, sex, BMI, and rate of diabetes. Biologic mesh patients had larger hernia defects (298 ± 233cm2 vs. 208 ± 155cm2; p = 0.004) and a higher rate of recurrent hernias (72.2% vs 47.1%; p < 0.001), comorbidities(5.8 ± 2.7 vs. 4.2 ± 2.4, p < 0.01), and a nearly fivefold increase in Class 4 wounds (47.8% vs. 9.8%, p < 0.001), while fascial closure trended to being less common (90.7% vs 96.1%; p = 0.078). Hernia recurrence was comparable between biologic and synthetic mesh (10.4% vs. 17.6%, p = 0.132). Wound complication rates were similar (36.1% vs. 33.3%, p = 0.699), but synthetic mesh had higher rates of mesh infection (1.2% vs 11.8%; p < 0.001) and infection-related resection (0% vs 7.8%, p < 0.001), with 66% of those synthetic mesh infections requiring excision. On logistic regression, wound complications (OR 5.96 [CI 1.60-22.17]; p = 0.008) and bridging mesh (OR 13.10 [CI 2.71-63.42];p = 0.030) predicted of hernia recurrence (p < 0.05), while synthetic mesh (OR 18.6 [CI 2.35-260.4] p = 0.012) and wound complications (OR 20.6 [CI 3.15-417.7] p = 0.008) predicted mesh infection.
CONCLUSIONS: Wound complications in AWR with CDC class 3 and 4 wounds significantly increased mesh infection and hernia recurrence; failure to achieve fascial closure also increased hernia recurrence. Use of synthetic versus biologic mesh increased the mesh infection rate by 18.6 times.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Abdominal wall reconstruction; Biologic mesh; Contaminated; Hernia; Mesh choice; Ventral hernia repair

Year:  2022        PMID: 35925400     DOI: 10.1007/s00464-022-09486-2

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  42 in total

Review 1.  A review of available prosthetics for ventral hernia repair.

Authors:  Vidya Shankaran; Daniel J Weber; R Lawrence Reed; Fred A Luchette
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

Review 2.  Prevention and Treatment Strategies for Mesh Infection in Abdominal Wall Reconstruction.

Authors:  Angela M Kao; Michael R Arnold; Vedra A Augenstein; B Todd Heniford
Journal:  Plast Reconstr Surg       Date:  2018-09       Impact factor: 4.730

3.  Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia.

Authors:  Jacobus W A Burger; Roland W Luijendijk; Wim C J Hop; Jens A Halm; Emiel G G Verdaasdonk; Johannes Jeekel
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

4.  A dual-stage approach to contaminated, high-risk ventral hernia repairs.

Authors:  Nathan W Kugler; Melanie Bobbs; Travis Webb; Thomas W Carver; David Milia; Jasmeet S Paul
Journal:  J Surg Res       Date:  2016-05-06       Impact factor: 2.192

5.  Preperitoneal Ventral Hernia Repair: A Decade Long Prospective Observational Study With Analysis of 1023 Patient Outcomes.

Authors:  B Todd Heniford; Samuel W Ross; Blair A Wormer; Amanda L Walters; Amy E Lincourt; Paul D Colavita; Kent W Kercher; Vedra A Augenstein
Journal:  Ann Surg       Date:  2020-02       Impact factor: 12.969

6.  Multicenter, Prospective, Longitudinal Study of the Recurrence, Surgical Site Infection, and Quality of Life After Contaminated Ventral Hernia Repair Using Biosynthetic Absorbable Mesh: The COBRA Study.

Authors:  Michael J Rosen; Joel J Bauer; Marco Harmaty; Alfredo M Carbonell; William S Cobb; Brent Matthews; Matthew I Goldblatt; Don J Selzer; Benjamin K Poulose; Bibi M E Hansson; Camiel Rosman; James J Chao; Garth R Jacobsen
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

7.  Major Complex Abdominal Wall Repair in Contaminated Fields with Use of a Non-cross-linked Biologic Mesh: A Dual-Institutional Experience.

Authors:  J J Atema; E J Furnée; Y Maeda; J Warusavitarne; P J Tanis; W A Bemelman; C J Vaizey; M A Boermeester
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

8.  Long-term outcomes after contaminated complex abdominal wall reconstruction.

Authors:  F E E de Vries; J D Hodgkinson; J J M Claessen; O van Ruler; C A Leo; Y Maeda; O Lapid; M C Obdeijn; P J Tanis; W A Bemelman; J Constantinides; G B Hanna; J Warusavitarne; C Vaizey; M A Boermeester
Journal:  Hernia       Date:  2020-02-20       Impact factor: 4.739

9.  Biologic mesh is non-inferior to synthetic mesh in CDC class 1 & 2 open abdominal wall reconstruction.

Authors:  Jenny M Shao; Sullivan A Ayuso; Eva B Deerenberg; Sharbel A Elhage; Tanu Prasad; Paul D Colavita; Vedra A Augenstein; B Todd Heniford
Journal:  Am J Surg       Date:  2021-06-10       Impact factor: 2.565

Review 10.  What is the evidence for the use of biologic or biosynthetic meshes in abdominal wall reconstruction?

Authors:  F Köckerling; N N Alam; S A Antoniou; I R Daniels; F Famiglietti; R H Fortelny; M M Heiss; F Kallinowski; I Kyle-Leinhase; F Mayer; M Miserez; A Montgomery; S Morales-Conde; F Muysoms; S K Narang; A Petter-Puchner; W Reinpold; H Scheuerlein; M Smietanski; B Stechemesser; C Strey; G Woeste; N J Smart
Journal:  Hernia       Date:  2018-01-31       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.